热带病与寄生虫学

热带病与寄生虫学 ›› 2013, Vol. 11 ›› Issue (4): 220-222.doi: 10.3969/j.issn.1672-2302.2013.03.011

• 论著 • 上一篇    下一篇

扶正化瘀胶囊治疗血吸虫性肝纤维化效果观察

吴志春，何峰   

  1. 安庆市第一人民医院感染病科
  • 出版日期:2013-04-25 发布日期:2014-02-19

Curative effect of Fuzheng Huayu capsule on schistosomiasis hepatic fibrosis

Wu zhichun, He feng   

  1. Department of Infectious Diseases, First People’s Hospital of Anqing
  • Online:2013-04-25 Published:2014-02-19

被引次数

1

摘要： 目的  探讨扶正化瘀胶囊治疗血吸虫性肝纤维化的疗效及其不良反应。 方法  将日本血吸虫性肝纤维化患者64例，随机分为对照组（基础护肝治疗组）31例和实验组（基础护肝联合扶正化瘀胶囊治疗组）33例，观察两组在治疗前后肝功能、血清肝纤维化指标的变化，临床症状及其不良反应等。 结果  治疗6个月，实验组患者治疗后血清丙氨酸氨基转移酶、门冬氨酸氨基转移酶、白蛋白、总胆红素等水平改善幅度较对照组更为显著，两组差异均有统计学意义（P＜0.05）；对照组HA、PCⅢ、Ⅳ-C及LN治疗后较治疗前有所下降，但差异均无统计学意义（P＞0.05），实验组HA、PCⅢ、Ⅳ-C及LN治疗后均较治疗前有所下降，差异有统计学意义（P＜0.05）。对照组与实验组患者症状明显好转率分别为61.3%、87.9%，实验组优于对照组，两者差异有统计学意义（P＜0.05）；对照组与实验组不良反应发生率分别为3.2%、3.0%，发生率均较低，两者差异无统计学意义（P＞0.05）。 结论  扶正化瘀胶囊治疗血吸虫性肝纤维化具有高效、安全的特点，值得高度重视及推广应用。

关键词: font-family: 宋体, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-font-kerning: 1.0pt, mso-bidi-font-family: 'Times New Roman', mso-ascii-font-family: 'Times New Roman', mso-hansi-font-family: 'Times New Roman'">扶正化瘀胶囊, 血吸虫病, 肝纤维化, 疗效, 不良反应

Abstract:

Objective  To evaluate the curative effect and adverse reaction of Fuzheng Huayu capsule on schistosomiasis hepatic fibrosis. Methods  Sixty-four cases of patients with schistosomiasis hepatic fibrosis were randomly divided into two groups, namely the control group(conventional protection liver therapeutics) and the experimental group(conventional protection liver therapeutics associating with Fuzheng Huayu capsule). Liver function, serum indexes of liver fibrosis, clinical symptoms and adverse reaction of the drugs were observed before and after the treatment. Results  After 6 months of the treatment, the improvement levels of ALT, AST, ALB and TBIL for the patients in the experimental group were more significant than that in the control group, and there were statistically significant difference (P＜0.05). HA, PC Ⅲ, Ⅳ -C and LN in the control group decreased, but there were no statistically significant difference before and after the treatment(P＞0.05). While HA, PC Ⅲ, Ⅳ -C and LN in the control group decreased, and there were statistically significant difference before and after treatment(P＜0.05). The improvement rate of symptoms in the experimental group(87.9%) were higher than that in the control group(61.3%), and there were statistically significant difference between the two groups(P＜0.05). There were no statistically significant difference for the adverse reaction rate between the control group(3.2%) and the experimental group(3.0%)(P＞0.05). Conclusion  Fuzheng Huayu Capsule has characteristics of high efficiency and safety in the treatment of schistosomiasis hepatic fibrosis, which is worth of attention and application.

Key words: font-family: "Times New Roman", mso-fareast-font-family: 宋体, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-font-kerning: 1.0pt">Fuzheng Huayu capsule, Schistosomiasis, Hepatic fibrosis, Curative effect, Adverse reaction